Skip to content
Independent reporting

Judges Allow Lawsuit Against FDA Over Anti-Ivermectin Propaganda to Continue

Share X Facebook Email

(Headline USA) A federal appeals court Friday revived a lawsuit by three doctors who say the Food and Drug Administration overstepped its authority in a campaign against treating COVID-19 with ivermectin.

Ivermectin is commonly used to treat parasites in livestock. It can also be prescribed for humans and it has been championed by some conservatives as a treatment for COVID-19.

The agency did not immediately respond to requests for comment.

Fridayโ€™s ruling from a panel of three judges on the 5th U.S. Circuit Court of Appeal in New Orleans focused on various aspects of an FDA campaign against ivermectin as a COVID-19 treatment.

The ruling said the campaign โ€” which at times featured the slogan โ€œYou are not a horse!โ€ โ€” too often left out that the drug is sometimes prescribed for humans.

The doctors can proceed with their lawsuit contending that the FDAโ€™s campaign exceeded the agencyโ€™s authority under federal law, the ruling said.

โ€œFDA is not a physician. It has authority to inform, announce, and appriseโ€”but not to endorse, denounce, or advise,โ€ Judge Don Willett wrote for a panel that also included Jennifer Walker Elrod and Edith Brown Clement. โ€œThe Doctors have plausibly alleged that FDAโ€™s Posts fell on the wrong side of the line between telling about and telling to.โ€

Drs. Robert L. Apter, Mary Talley Bowden and Paul E. Marik filed the lawsuit last year. All three said their reputations were harmed by the FDA campaign. Bowden lost admitting privileges at a Texas hospital, the ruling noted. Marik alleged he lost his positions at a medical school and at a hospital for promoting the use of ivermectin.

The lawsuit was dismissed in December by U.S. District Judge Jeffrey Vincent Brown, who ruled that the complaints didnโ€™t overcome the FDAโ€™s โ€œsovereign immunity,โ€ a concept that protects government entities from many civil lawsuits regarding their responsibilities. The appellate panel said the FDAโ€™s alleged overstepping of its authority opened the door for the lawsuit.

Adapted from reporting by the Associated Press

Source

Share X Facebook Email

The Daily Brief

The essential stories, without the noise.

A concise briefing delivered directly to your inbox.

Free to join. Unsubscribe any time.

Powered by Reach Response